Pioglitazone Identifies a New Target for Aneurysm Treatment: Role of Egr1 in an Experimental Murine Model of Aortic Aneurysm

J Vasc Res. 2015;52(2):81-93. doi: 10.1159/000430986. Epub 2015 Jun 20.

Abstract

Peroxisome proliferator-activated receptor x03B3; agonists have been shown to inhibit angiotensin II (AngII)-induced experimental abdominal aortic aneurysms. Macrophage infiltration to the vascular wall is an early event in this pathology, and therefore we explored the effects of the peroxisome proliferator-activated receptor x03B3; agonist pioglitazone on AngII-treated macrophages. Using microarray-based expression profiling of phorbol ester-stimulated THP-1 cells, we found that a number of aneurysm-related gene changes effected by AngII were modulated following the addition of pioglitazone. Among those genes, polycystic kidney disease 1 (PKD1) was significantly up-regulated (multiple testing corrected p < 0.05). The analysis of the PKD1 proximal promoter revealed a putative early growth response 1 (EGR1) binding site, which was confirmed by chromatin immunoprecipitation (ChIP) and quantitative PCR. Further analysis of publicly available ChIP-sequencing data revealed that this putative binding site overlapped with a conserved EGR1 binding peak present in 5 other cell lines. Quantitative real-time PCR showed that EGR1 suppressed PKD1, while AngII significantly up-regulated PKD1, an effect counteracted by pioglitazone. Conversely, in EGR1 short hairpin RNA lentivirally transduced THP-1 cells, reduced EGR1 led to a significant up-regulation of PKD1, especially after treatment with pioglitazone. In vivo, deficiency of Egr1 in the haematopoietic compartment of mice completely abolished the incidence of CaCl2-induced aneurysm formation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • Aortic Aneurysm, Abdominal / chemically induced
  • Aortic Aneurysm, Abdominal / genetics
  • Aortic Aneurysm, Abdominal / metabolism
  • Aortic Aneurysm, Abdominal / prevention & control*
  • Base Sequence
  • Binding Sites
  • Calcium Chloride
  • Cell Line, Tumor
  • Disease Models, Animal
  • Early Growth Response Protein 1 / deficiency
  • Early Growth Response Protein 1 / genetics
  • Early Growth Response Protein 1 / metabolism*
  • Female
  • Gene Expression Profiling / methods
  • Gene Expression Regulation
  • Humans
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Male
  • Mice, Knockout
  • Molecular Sequence Data
  • PPAR gamma / agonists
  • PPAR gamma / metabolism
  • Pioglitazone
  • Promoter Regions, Genetic
  • RNA Interference
  • Signal Transduction / drug effects
  • TRPP Cation Channels / genetics
  • TRPP Cation Channels / metabolism
  • Thiazolidinediones / pharmacology*
  • Time Factors
  • Transfection

Substances

  • EGR1 protein, human
  • Early Growth Response Protein 1
  • Egr1 protein, mouse
  • PPAR gamma
  • TRPP Cation Channels
  • Thiazolidinediones
  • polycystic kidney disease 1 protein
  • Angiotensin II
  • Calcium Chloride
  • Pioglitazone